Prostate Cancer | Specialty

ESMO 2018: Dr. Moore Speaks to Exciting PARP Inhibitor Abstracts in Ovarian Cancer

October 21st 2018

OncLive News Network On Location: In Munich Monday, October 22

October 21st 2018

OncLive News Network On Location: In Munich Sunday, October 21

October 21st 2018

OncLive News Network On Location: In Munich Saturday, October 20

October 21st 2018

Adding Radium-223 to Abiraterone Shows No Survival Advantage in mCRPC

October 20th 2018

Adding radium-223 dichloride to abiraterone acetate and prednisone did not improve survival in patients with metastatic castration-resistant prostate cancer.

Dr. Bradley on Impact of SPARTAN and PROSPER in Nonmetastatic CRPC

October 19th 2018

Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, discusses the impact of the recently published SPARTAN and PROSPER trials in nonmetastatic castration-resistant prostate cancer.

Dr. Kearns on the Role of Surgery in High-Risk Prostate Cancer

October 19th 2018

James Kearns, MD, assistant professor of urology, Levine Cancer Institute, discusses the role of surgery in patients with high-risk prostate cancer.

Gomella Gives Update on Nonmetastatic CRPC Advances

October 19th 2018

Leonard G. Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, discusses the shifting landscape of nonmetastastic CRPC, along with other developments across the prostate cancer paradigm.

Dr. Sweis on Sequencing of Therapies in Prostate Cancer

October 12th 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the sequencing of therapies in prostate cancer.

Dr. Daskivich Discusses Active Surveillance in Prostate Cancer

October 10th 2018

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses active surveillance for patients with prostate cancer.

Dr. Sharma Discusses Immunotherapy in Prostate Cancer

October 5th 2018

Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immunotherapy in prostate cancer.

Prostate Cancer Paradigm Progresses, But Unanswered Questions Remain

October 4th 2018

Randy F. Sweis, MD, discusses recent progress and next steps in the prostate cancer paradigm.

Dr. Steinberg on the Management of Prostate Cancer

October 2nd 2018

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the management of patients with prostate cancer.

FDA Grants Rucaparib Breakthrough Designation for mCRPC

October 2nd 2018

The FDA has granted the PARP inhibitor rucaparib a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer following at least 1 androgen receptor–directed therapy and taxane-based chemotherapy.

Challenges Remain in Prostate Cancer Paradigm

September 25th 2018

Walter M. Stadler, MD, gives an overview of the current prostate cancer landscape and discussed future directions.

Dr. Stadler on Sequencing Therapies in Prostate Cancer

September 22nd 2018

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses sequencing therapies in prostate cancer.

Patient-Centered Focus Drives Growth at Virginia Urology

September 19th 2018

Virginia Urology, a practice with specialists in surgery, radiation, and oncology, has grown steadily over 75 years by remaining patient focused. Centered in Richmond, Virginia Urology has always prioritized quality care.

Dr. Daskivich on the Future Landscape of Prostate Cancer

September 19th 2018

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses the future treatment landscape of prostate cancer.

Personalized Medicine in Prostate Cancer: Now More Precise

September 18th 2018

Raoul S. Concepcion, MD, FACS, discusses the explosion of molecular testing in the urology world.

Apalutamide Maintains Health-Related QoL in Nonmetastatic CRPC

September 17th 2018

Fred Saad, MD, discusses the clinical significance of the SPARTAN trial, the HRQoL data, and remaining steps in the treatment of patients with nonmetastatic castration-resistant prostate cancer.